Denali Therapeutics Inc (NASDAQ:DNLI) shares are moving lower in Thursday’s after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued. What Happened ...

In this article, we are going to take a look at where Denali Therapeutics Inc. (NASDAQ:DNLI) stands against the other stocks Jeff Bezos is buying. Jeff Bezos is a name closely tied to Amazon the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Jefferies raised the firm’s price target on Denali Therapeutics (DNLI) to $45 from $40 and keeps a Buy rating on the shares ahead of the company reporting first DNL-126 Phase 1/2 data in ...

In a report released today, Michael Yee from Jefferies maintained a Buy rating on Denali Therapeutics (DNLI – Research Report), with a ...

On Friday, Denali Therapeutics Inc (DNLI) stock saw a modest uptick, ending the day at $27.05 which represents a slight increase of $1.09 or 4.20% from the prior close of $25.96. The stock opened at ...

On Monday, Denali Therapeutics Inc (DNLI) stock saw a modest uptick, ending the day at $27.78 which represents a slight increase of $1.63 or 6.23% from the prior close of $26.15. The stock opened at ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Denali Therapeutics Inc. (DNLI) reports results for the quarter ended September 2024. While this widely-known ...

Federal highway officials on Thursday announced $635 million to repair or replace numerous old and outdated bridges ranging from Alaska to Maine, including a couple located in popular national parks.

Denali Therapeutics announces its Phase 2 study of oditrasertib was discontinued. Denali's strategic partner says the study failed to meet the primary and key secondary endpoints. Denali ...